High-alert medication classification
A
high-alert medication is a drug that carries a heightened risk of causing significant patient harm when it is used in error. The harm is not necessarily more frequent than with other drugs, but the consequences of an error are more serious. The Institute for Safe Medication Practices (ISMP) maintains a widely used list of high-alert medications, and hospital-specific lists are often built from that foundation. In this patient, the admitting diagnoses and medication history include several drugs that require safeguards, but the question asks which single option is classified as high-alert.
Intravenous morphine is an opioid, and opioids are consistently included on high-alert medication lists because of the risk of respiratory depression, oversedation, and death when dosing or monitoring errors occur. The ISMP high-alert list explicitly names intravenous opioids, along with insulin, anticoagulants, concentrated electrolytes, neuromuscular blocking agents, chemotherapy, and intravenous sedatives. Morphine given by the intravenous route has a rapid onset and a narrow margin for error, which is why independent double-checks, smart pump limits, and frequent respiratory assessment are standard safeguards.
The other options do not meet the high-alert definition.
Intravenous clindamycin is an antibiotic; although it can cause infusion-related reactions or
Clostridioides difficile–associated diarrhea, routine antibiotics are not on the ISMP high-alert list.
Oral amlodipine is a calcium channel blocker used for hypertension; oral calcium channel blockers are not classified as high-alert, unlike certain intravenous vasoactive calcium channel blockers such as intravenous diltiazem or verapamil, which do appear on some institutional lists.
Oral paracetamol is a routine analgesic and antipyretic; it is not a high-alert medication, although hepatotoxicity is a concern in overdose.
Key point! The high-alert classification is based on the potential for catastrophic harm from an error, not on how commonly the drug is used or how dangerous it is when used correctly. A drug can be safe in routine use and still be high-alert because an error would be devastating.
The distinction matters in this patient because he is already receiving or may receive several high-alert drugs. His
atrial fibrillation likely requires an anticoagulant, his
type 2 diabetes with a capillary blood glucose of
286 mg/dL (15.9 mmol/L) may require insulin, and his infected foot ulcer may require intravenous antibiotics. The anticoagulant and insulin are high-alert, but they are not among the answer choices. The question isolates the principle: among the listed options, only the intravenous opioid is high-alert.
Watch out! Do not confuse “high-alert” with “controlled substance.” Morphine is both a controlled substance and a high-alert medication, but the two categories are not the same. Controlled substance status relates to abuse and diversion potential, while high-alert status relates to the risk of serious patient harm from a medication error.
The systematic review by Sodré Alves et al. examined harm prevalence from medication errors involving high-alert medications in hospitals. The reported prevalence of harm varied widely across studies, from
3.8% to
100%, reflecting differences in definitions, settings, and reporting methods. The wide range underscores that harm from high-alert medication errors is a real and measurable problem, but it also shows that the classification itself is only the starting point.
The presence of a drug on a high-alert list signals that the organization must build specific safeguards around prescribing, dispensing, preparation, administration, and monitoring.
Schepel et al. add another layer: high-alert medication lists should be customized to the local context using hospital-specific safety data. Their analysis of adverse drug reaction and medication error reports at Helsinki University Hospital showed that a national or international list is a useful starting point, but institutions should review their own error data to identify which drugs actually cause harm in their setting. This does not change the core classification of intravenous morphine as high-alert; rather, it explains why a ward may add or remove drugs from a local list based on its own incident reports.
| Medication | Class | High-alert status | Primary error-related risk |
|---|
| Intravenous morphine | Opioid analgesic | Yes | Respiratory depression, oversedation, death |
| Intravenous clindamycin | Antibiotic | No | Infusion reaction, C. difficile infection |
| Oral amlodipine | Calcium channel blocker | No | Hypotension, peripheral edema |
| Oral paracetamol | Non-opioid analgesic | No | Hepatotoxicity in overdose |
For the nursing licensure examinee, the practical application is straightforward: when you see an opioid, an anticoagulant, insulin, a concentrated electrolyte, a neuromuscular blocker, chemotherapy, or an intravenous sedative, recognize that extra safeguards are required. These safeguards include independent double-checks, standardized concentrations, smart infusion pump limits, and more frequent monitoring. In this patient, the
INR of 2.6 signals that his anticoagulation is already in a therapeutic range that requires close monitoring, and his elevated blood glucose signals that insulin may be needed. Both are high-alert, but the question asks only about the listed options, and the correct answer is the intravenous opioid.